Search
Trilostane
go.drugbank.com/drugs/DB01108ApprovedVet approvedWithdrawnTrilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedIt can be used in patients with compensated cirrhosis, human immunodeficiency virus co-infection, or severe kidney disease. … Grazoprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis].
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigationalNaxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside. … [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely
Ivabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate … Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the
Ibudilast
go.drugbank.com/drugs/DB05266InvestigationalIbudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigational[A179209] Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- … It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitorsSpironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigationalSpironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. … [A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension.
Categories: Mineralocorticoid Receptor Antagonists, Mineralocorticoid (Aldosterone) Receptor AntagonistsFerrous ascorbate
go.drugbank.com/drugs/DB14490ApprovedWithdrawnCategories: Compounds used in a research, industrial, or household settingClavulanic acid
go.drugbank.com/drugs/DB00766ApprovedInvestigationalVet approved[A182228]When it is combined with amoxicillin, clavulanic acid is frequently known as Augmentin, Co-Amoxiclav, or Clavulin.[L7880,L7904,L7910] … [T665] Clavulanic acid is derived from the organism Streptomyces clavuligerus.
Mixtures: CROXILEX 1.2G IV ENJEKSİYON İÇİN TOZ İÇEREN FLAKON, Amoklavin 1000 mg/200 mg IV Enjeksiyonluk/İnfüzyonluk Çözelti Hazırlamak İçin Toz ve ÇözücüIsavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalIt is proposed that the intravenous and oral dosing can be used interchangeably [L1482], without the need for a repeat loading dose when transitioning from an IV to an oral formulation [A32026]. … As isavuconazole displays low water solubility, it is found as an active ingredient of its prodrug, [DB06636].